Table 2.
Data, means, and p values of groups before treatment, and in the first and third months of treatment
| Variable | n | Mean ± SD | p | |
|---|---|---|---|---|
| IPSS (0) | 0.206 | |||
| First group | 31 | 16.5 ± 8.5 | ||
| Placebo group | 31 | 15.9 ± 7.08 | ||
| IPSS (1st) | ||||
| First group | 31 | 16.0 ± 7.4 | ||
| Placebo group | 31 | 16.8 ± 7.72 | ||
| IPSS (3rd) | ||||
| First group | 31 | 15.7 ± 7.6 | ||
| Placebo group | 31 | 17.8 ± 8.3 | ||
| Qmax, ml/s (0) | 0.019 | |||
| First group | 31 | 16.4 ± 8.84 | ||
| Placebo group | 31 | 16.2 ± 8.2 | ||
| Qmax, ml/s (1st) | ||||
| First group | 31 | 17.7 ± 9.25 | ||
| Placebo group | 31 | 15.4 ± 7.54 | ||
| Qmax, ml/s (3rd) | ||||
| First group | 31 | 18.4 ± 9.29 | ||
| Placebo group | 31 | 13.7 ± 8.27 | ||
| AMS-Q (0) | < 0.001 | |||
| First group | 31 | 52.1 ± 14.5 | ||
| Placebo group | 31 | 60 ± 11.8 | ||
| AMS-Q (1st) | ||||
| First group | 31 | 42.1 ± 12.7 | ||
| Placebo group | 31 | 60 ± 11.9 | ||
| AMS-Q (3rd) | ||||
| First group | 31 | 37.4 ± 11.2 | ||
| Placebo group | 31 | 60 ± 11.7 | ||
| IIEF-5 (0) | < 0.001 | |||
| First group | 31 | 15 ± 5 | ||
| Placebo group | 31 | 12.7 ± 4.64 | ||
| IIEF-5 (1st) | ||||
| First group | 31 | 18.5 ± 4.4 | ||
| Placebo group | 31 | 12 ± 4.57 | ||
| IIEF-5 (3rd) | ||||
| First group | 31 | 19.6±4.18 | ||
| Placebo group | 31 | 12 ± 4.71 | ||
| PSA, ng/dl (0) | 0.786 | |||
| First group | 31 | 2.1 ± 0.7 | ||
| Placebo group | 31 | 1.9 ± 0.8 | ||
| PSA, ng/dl (1st) | ||||
| First group | 31 | 2.2 ± 0.5 | ||
| Placebo group | 31 | 2.1 ± 0.7 | ||
| PSA, ng/dl (3rd) | ||||
| First group | 31 | 1.9 ± 0.7 | ||
| Placebo group | 31 | 2.1 ± 0.9 |